Contact
 

A major step in HIV vaccine research, but much more to do

Science Speaks HIV and TB News yesterday published a Q&A with Louis Picker, associate director of the Oregon Health & Science University’s Vaccine and Gene Therapy Institute (VGTI). Picker led a team of researchers that tested in nonhuman primates an experimental vaccine construct based on a modified cytomegalovirus (CMV) vector that is capable of establishing a long-term presence in the body. The study, which was published in the advance online edition of the journal Nature last week, found that just over half of the rhesus macaques that received the candidate vaccine were able to control their infections, their viral loads dropping to levels that even the most sensitive tests cannot detect. The National Cancer Institute-Frederick and IAVI were collaborators on this study and provided funding. Read the full story here.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account